Sustained GLP-1 receptor agonist therapy is linked to greater improvements in A1c levels than DPP-4 inhibitor therapy in patients with type 2 diabetes, a Danish real-world analysis shows.

In older adults with type 2 diabetes (T2D), the initiation of GLP-1 receptor agonists vs drugs such as DPP-4 and SGLT2 inhibitors was associated with an 11% increased risk for fragility fractures.

Israel: Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for their glycemic and cardiovascular benefits in type 2 diabetes, may be linked to a modestly higher risk of fragility ...

Retrospective study finds link between blockbuster drugs and longer survival ...

The most recent version of NG28, the National Institute for Health and Care Excellence's (NICE) guidelines for managing type 2 diabetes in adults, has been released on February 18, 2026.

Burn Slim announces an official consumer safety warning after counterfeit and tainted versions of its natural GLP-1 mimetic weight loss formula were identified on unauthorized retail platforms and ...

Burn Slim is a natural dietary supplement built around one of the most searched weight loss strategies of 2026: the "gelatin ...

The global type 2 diabetes market size surpassed USD 40.09 billion in 2025 and is projected to reach approximately USD 79.25 ...

The fountain of youth may be flowing through your veins. A new study out of Switzerland identified key proteins in the blood of centenarians that appear to be linked to slower aging. Scientists say ...

News and commentary from the endocrinology world ...

The "Swiss 100" study identified in the blood of centenarians 37 proteins whose profile appears to be linked to slowed aging.

A peer-reviewed study of more than 46,000 older adults with type 2 diabetes found that patients who started GLP-1 receptor agonist drugs faced an 11 percent higher risk of fragility fractures compared ...